Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
VVUS [NASD]
VIVUS Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own0.60% Shs Outstand103.45M Perf Week0.72%
Market Cap434.49M Forward P/E- EPS next Y-1.32 Insider Trans-18.72% Shs Float102.47M Perf Month-14.29%
Income-106.90M PEG- EPS next Q-0.26 Inst Own79.60% Short Float36.12% Perf Quarter-9.48%
Sales130.00M P/S3.34 EPS this Y-21.80% Inst Trans6.94% Short Ratio18.68 Perf Half Y-37.78%
Book/sh1.15 P/B3.65 EPS next Y-33.30% ROA-25.50% Target Price6.13 Perf Year-66.13%
Cash/sh3.13 P/C1.34 EPS next 5Y4.70% ROE-75.30% 52W Range4.06 - 12.95 Perf YTD-53.74%
Dividend- P/FCF- EPS past 5Y-65.30% ROI-42.20% 52W High-67.57% Beta1.42
Dividend %- Quick Ratio6.60 Sales past 5Y-0.60% Gross Margin84.20% 52W Low3.45% ATR0.18
Employees98 Current Ratio7.50 Sales Q/Q298.20% Oper. Margin-33.80% RSI (14)34.47 Volatility3.13% 4.22%
OptionableYes Debt/Eq1.82 EPS Q/Q54.50% Profit Margin-82.20% Rel Volume0.36 Prev Close4.20
ShortableYes LT Debt/Eq1.82 EarningsAug 07 AMC Payout- Avg Volume1.98M Price4.20
Recom3.60 SMA20-7.31% SMA50-13.15% SMA200-35.44% Volume707,087 Change0.00%
25-Feb-14Reiterated WallachBeth Hold $11 → $8
15-Nov-13Initiated WallachBeth Hold $11
03-Oct-13Upgrade Cowen Hold → Outperform $19
19-Jul-13Downgrade Needham Buy → Hold
18-Jan-13Reiterated MLV & Co Buy $40 → $21
24-Sep-12Reiterated Needham Buy $38 → $32
19-Jul-12Reiterated MLV & Co Buy $34 → $40
18-Jul-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
18-Jul-12Downgrade Brean Murray Buy → Hold
30-Apr-12Reiterated MLV & Co Buy $30 → $34
23-Feb-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
23-Feb-12Upgrade Brean Murray Sell → Hold $2
23-Feb-12Reiterated MLV & Co Buy $22 → $30
23-Feb-12Reiterated JMP Securities Mkt Outperform $16 → $45
17-Jan-12Reiterated MLV & Co Buy $16 → $22
05-Jan-12Initiated Rodman & Renshaw Mkt Perform
29-Oct-10Reiterated JMP Securities Mkt Outperform $12 → $16
03-Aug-10Downgrade Brean Murray Hold → Sell $2
16-Jul-10Reiterated Wedbush Outperform $20 → $10
16-Jul-10Reiterated JMP Securities Mkt Outperform $18 → $12
19-Aug-14 10:45AM  You've got obesity all wrong: Zafgen CEO at CNBC
18-Aug-14 06:26AM  [video] Obesity treatment sales fall short at CNBC
15-Aug-14 04:05PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
01:04PM  VIVUS INC Financials EDGAR Online Financials
12-Aug-14 04:10PM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
01:58PM  Auxilium Posts Wider-than-Expected Loss, Outlook Maintained Zacks
08-Aug-14 10:00AM  VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales Zacks
07-Aug-14 04:30PM  Vivus Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:18PM  Vivus Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:10PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  VIVUS Reports Second Quarter 2014 Financial Results Marketwired
07:35AM  Vivus Inc Earnings Call scheduled for 4:30 pm ET today CCBN
07:07AM  Q2 2014 Vivus Inc. Earnings Release - After Market Close CCBN
06-Aug-14 05:00PM  Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? Zacks
04:10PM  Will Mylan (MYL) Earnings in Q2 Disappoint Expectations? Zacks
04-Aug-14 10:10AM  Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss Zacks
31-Jul-14 07:00AM  VIVUS Announces Date of Second Quarter 2014 Update and Financial Results Conference Call GlobeNewswire -5.68%
19-Jul-14 04:14PM  The Implications of Obesity as a Disability in Europe at Motley Fool
15-Jul-14 06:49PM  Lightning Round: Akamai, GE & more at CNBC
11-Jul-14 05:02PM  3 Crashing Biotechs: Is 1 a Buy? at Motley Fool
03:45PM  Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force Zacks
03-Jul-14 04:11PM  3 Stocks Even Volatility-Loving Nasdaq Investors Hate at Motley Fool
27-Jun-14 05:30PM  Are Investors Wrong About Orexigen Therapeutics?
12:37PM  Arena's Belviq Sales Flat Again at Seeking Alpha
12:37PM  Arena's Belviq Sales Flat Again
25-Jun-14 05:30PM  Are Investors Wrong About VIVUS? at Motley Fool
05:30PM  Are Investors Wrong About VIVUS?
24-Jun-14 06:20AM  How Bad Is This Delay for Orexigen Therapeutics, Inc? at Motley Fool
06:20AM  How Bad Is This Delay for Orexigen Therapeutics, Inc?
23-Jun-14 12:01AM  Early Results Arrive on Weight-Loss Pills That Expand in the Stomach at New York Times
12:01AM  Early Results Arrive on Weight-Loss Pills That Expand in the Stomach
20-Jun-14 11:34AM  The Anti-Obesity Space Is Not As Simple As Some Think at Seeking Alpha
11:34AM  The Anti-Obesity Space Is Not As Simple As Some Think
03:19AM  Now Available: Shares in Zafgen, the Best Obesity Drugmaker to Date at Motley Fool
03:19AM  Now Available: Shares in Zafgen, the Best Obesity Drugmaker to Date
19-Jun-14 03:12PM  Why Zafgen Inc. Shares Roared Higher at Motley Fool
17-Jun-14 05:05PM  VIVUS INC Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
05:05PM  VIVUS INC Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits
07:05AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
07:05AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
16-Jun-14 04:19PM  What Will It Take For Arena Stock To Rise? at Seeking Alpha
04:19PM  What Will It Take For Arena Stock To Rise?
13-Jun-14 04:05PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:05PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
02:56PM  Vivus Suit Preserves Exclusivity Of Qsymia - For Now at Seeking Alpha
02:56PM  Vivus Suit Preserves Exclusivity Of Qsymia - For Now
01:22PM  5 Stocks Poised for Breakouts at TheStreet
12-Jun-14 04:50PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:50PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:32PM  VIVUS Files Lawsuit Against Actavis for Infringement of Qsymia Patents Marketwired
04:32PM  VIVUS Files Lawsuit Against Actavis for Infringement of Qsymia Patents
08:00AM  EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel at TheStreet
08:00AM  EnteroMedics: A Preview of the Weight-Loss Zapper FDA Panel
07:00AM  VIVUS to Present at Upcoming Investor Conference Marketwired
11-Jun-14 05:07PM  Why Orexigen Therapeutics Inc. Shares Were Throttled at Motley Fool
05:02PM  Orexigen Irony: No VIVUS Bounce at 24/7 Wall St.
02:11PM  Why Orexigen Therapeutics is Falling Today at Motley Fool
12:02PM  Why Don't Doctors Prescribe More Weight-Loss Drugs? at BusinessWeek
11:55AM  Orexigen Obesity Drug Decision Delayed By FDA at Investor's Business Daily
11:34AM  Down 18%: Is Orexigen a Bad News Buy? at Motley Fool
10:07AM  Orexigen shares hit by FDA delay in obesity drug at CNBC
09:37AM  Top Swing Trade Ideas for Wednesday June 11: Facebook, Vivus, More at TheStreet
09:28AM  FDA Delays Decision On Orexigen Anti-Obesity Drug - What This Means To The Stock at Seeking Alpha
08:21AM  Ahead of the Bell: Orexigen Therapeutics slips AP
06:48AM  FDA Delays Decision on Orexigen Obesity Pill by 3 Months at TheStreet
10-Jun-14 01:22PM  Orexigen Investors Hope For FDA Approval at Seeking Alpha
09-Jun-14 05:22PM  Orexigen Could Be A Double-Edged Sword For Arena at Seeking Alpha
02:54PM  Is Vivus About To Get Squeezed? Benzinga
02:06PM  As Orexigen Faces FDA Will Weight Loss Landscape Change? at Motley Fool
01:39PM  [video] Expectations for new obesity drug at CNBC
12:45PM  Third time's a charm for Orexigen's obesity drug? at CNBC
12:45PM  Orexigen may give diet pill market the jolt it needs at CNBC
12:45PM  Obesity game-changer? Why this time it's different at CNBC
12:45PM  Obesity game changer? Why this time it's different at CNBC
12:43PM  Orexigen: 'Goldilocks' Obesity Pill Awaits FDA Approval Decision Wednesday at TheStreet
04:47AM  What's behind Vivus call selling optionMONSTER
06-Jun-14 01:15PM  Arena Pharmaceuticals: Strong Sell On Multiple Red Flags at Seeking Alpha
05-Jun-14 08:24PM  Don't Hold Your Breath Waiting for a VIVUS Inc. Buyout at Motley Fool
03-Jun-14 08:01AM  Investors Are Shorting VIVUS (VVUS) Stock: Is A Short Cover Coming? Zacks
31-May-14 01:34PM  Is Arena or VIVUS the Better Obesity Drug Stock? at Motley Fool
30-May-14 04:46PM  Belviq Sales Climb - Are Ads Effective? at Seeking Alpha
12:30PM  A Vivus Buyout? Fat Chance And A Good Time To Short at Seeking Alpha
29-May-14 06:47PM  Lightning Round: at CNBC
06:35PM  The Beginning of the (Merciful) End for VIVUS, Inc Shareholders? at Motley Fool
08:36AM  Today's Top Biotech Stocks to Watch: Intercept Pharmaceuticals and VIVUS at Motley Fool
06:50AM  VIVUS Inc. (VVUS) in Focus: Stock Up 6% Zacks
28-May-14 05:25PM  Why Ballard Power Systems, PTC Therapeutics, and VIVUS Are Today's 3 Best Stocks at Motley Fool +6.00%
04:56PM  Aspen Investment Said To Be Offering $640 Million For Vivus at Seeking Alpha
01:52PM  Why VIVUS Inc. Shares Spiked Higher at Motley Fool
12:18PM  Midday movers: Allergan, Apple, Brown Shoe Co. & More at CNBC
12:02PM  Aspen Buys 9.65% Stake In Vivus, May Acquire Added Holdings Benzinga
11:30AM  VIVUS issues 'no comment' on Aspen Investment offer, Bloomberg reports at theflyonthewall.com
11:17AM  Why Vivus (VVUS) Stock Is Up Today at TheStreet
10:46AM  [$$] Aspen Investment Considers Bid for Vivus at The Wall Street Journal
10:37AM  A Greek Lawyer Managing a Little-Known Investment Fund Wants to Buy Vivus for $640 Million at TheStreet
10:00AM  VIVUS rises 14.8% at theflyonthewall.com
09:55AM  Aspen Investment Fund says may offer $640M to buy VIVUS at theflyonthewall.com
09:51AM  Aspen Investment says considering VIVUS buyout offer for $640M at theflyonthewall.com
08:30AM  Orexigen's Weight Loss Drug Will Be Approved Soon And Will Lead Market - Here Is Why at Seeking Alpha
27-May-14 06:34PM  Obesity Hype Meets Harsh Reality at Motley Fool
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II clinical studies for the treatment of obstructive sleep apnea and diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fischer Seth H.Z.Chief Executive OfficerMar 11Buy6.073,08018,6953,080Mar 12 06:37 PM
DENNER ALEXANDER JDirectorNov 11Buy8.78149,7761,315,0332,573,943Nov 12 05:08 PM
DENNER ALEXANDER JDirectorNov 08Buy8.52417,0683,553,4192,424,167Nov 12 05:08 PM
MORRIS TIMOTHY EVP, Finance and CFOSep 05Option Exercise4.2310,65445,06610,654Sep 09 07:29 PM
MORRIS TIMOTHY EVP, Finance and CFOSep 05Sale11.9510,654127,2830Sep 09 07:29 PM
ASTRUE MICHAEL JDirectorSep 04Buy11.9610,000119,59710,000Sep 06 04:09 PM